JP2007524847A5 - - Google Patents

Download PDF

Info

Publication number
JP2007524847A5
JP2007524847A5 JP2006538558A JP2006538558A JP2007524847A5 JP 2007524847 A5 JP2007524847 A5 JP 2007524847A5 JP 2006538558 A JP2006538558 A JP 2006538558A JP 2006538558 A JP2006538558 A JP 2006538558A JP 2007524847 A5 JP2007524847 A5 JP 2007524847A5
Authority
JP
Japan
Prior art keywords
cystatin
alzheimer
biomarker
peptide
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006538558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524847A (ja
JP4796967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037994 external-priority patent/WO2005047484A2/en
Publication of JP2007524847A publication Critical patent/JP2007524847A/ja
Publication of JP2007524847A5 publication Critical patent/JP2007524847A5/ja
Application granted granted Critical
Publication of JP4796967B2 publication Critical patent/JP4796967B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2006538558A 2003-11-07 2004-11-06 アルツハイマー病のためのバイオマーカー Expired - Fee Related JP4796967B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US51836003P 2003-11-07 2003-11-07
US60/518,360 2003-11-07
US52675303P 2003-12-02 2003-12-02
US60/526,753 2003-12-02
US54642304P 2004-02-19 2004-02-19
US60/546,423 2004-02-19
US54725004P 2004-02-23 2004-02-23
US60/547,250 2004-02-23
US55889604P 2004-04-02 2004-04-02
US60/558,896 2004-04-02
US57261704P 2004-05-18 2004-05-18
US60/572,617 2004-05-18
US58650304P 2004-07-08 2004-07-08
US60/586,503 2004-07-08
PCT/US2004/037994 WO2005047484A2 (en) 2003-11-07 2004-11-06 Biomarkers for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011012368A Division JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Publications (3)

Publication Number Publication Date
JP2007524847A JP2007524847A (ja) 2007-08-30
JP2007524847A5 true JP2007524847A5 (https=) 2011-03-10
JP4796967B2 JP4796967B2 (ja) 2011-10-19

Family

ID=34596275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006538558A Expired - Fee Related JP4796967B2 (ja) 2003-11-07 2004-11-06 アルツハイマー病のためのバイオマーカー
JP2011012368A Expired - Fee Related JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011012368A Expired - Fee Related JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Country Status (4)

Country Link
US (2) US7794948B2 (https=)
EP (3) EP1694816B1 (https=)
JP (2) JP4796967B2 (https=)
WO (1) WO2005047484A2 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7707134B2 (en) * 2005-01-14 2010-04-27 Siemens Medical Solutions Usa, Inc. System and method for molecular diagnosis of depression based on boosting classification
FR2882171A1 (fr) * 2005-02-14 2006-08-18 France Telecom Procede et dispositif de generation d'un arbre de classification permettant d'unifier les approches supervisees et non supervisees, produit programme d'ordinateur et moyen de stockage correspondants
WO2006106115A2 (de) * 2005-04-06 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnose von alzheimer
WO2006110621A2 (en) * 2005-04-11 2006-10-19 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject
WO2006138355A2 (en) * 2005-06-14 2006-12-28 Albert Einstein College Of Medicine Of Yeshiva University Effect of bri proteins on abeta production
ATE511643T1 (de) 2005-06-16 2011-06-15 Vermillion Inc Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
WO2007012052A1 (en) * 2005-07-20 2007-01-25 Medical College Of Georgia Research Institute Use of protein profiles in disease diagnosis and treatment
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
JPWO2007105442A1 (ja) * 2006-02-22 2009-07-30 協和発酵キリン株式会社 摂食障害または摂水障害の治療薬
CA2689848A1 (en) * 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
JP5357746B2 (ja) * 2006-03-11 2013-12-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 末梢性の動脈疾患のためのバイオマーカーとしてのβ−２ミクログロブリン
WO2007136614A2 (en) * 2006-05-19 2007-11-29 Merck & Co., Inc. Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel
WO2007139777A2 (en) * 2006-05-26 2007-12-06 Merck & Co., Inc. Methods for the diagnosis and prognosis of alzheimer's disease using csf protein profiling
US7851172B2 (en) * 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20080117416A1 (en) * 2006-10-27 2008-05-22 Hunter Ian W Use of coherent raman techniques for medical diagnostic and therapeutic purposes, and calibration techniques for same
DE102006056337A1 (de) * 2006-11-29 2008-06-05 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2198292A4 (en) * 2007-08-21 2010-09-08 Univ Washington IMPROVED MORBUS ALZHEIMER DIAGNOSIS
EP2279420B1 (en) 2008-03-21 2014-01-29 Manuela G. Neuman METHODS FOR THE DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE VERSUS FRONTOTEMPORAL DEMENTIA, COMPRISING FAS-L, TNF-alpha AND ccCK-18 AS BIOMARKERS
JP5781436B2 (ja) 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
EP2344881A4 (en) * 2008-09-26 2012-03-07 Univ Melbourne BIOMARKER FOR MORBUS ALZHEIMER
GB0818650D0 (en) 2008-10-10 2008-11-19 Uni I Oslo Methods
EP2373999A4 (en) * 2008-12-09 2012-11-07 Stephanie Fryar-Williams NEW BIOMARKERS
EP2391379B1 (en) 2009-01-30 2017-08-02 Alphabeta AB Compound and method for treatment of alzheimer's disease
WO2011005893A2 (en) * 2009-07-07 2011-01-13 Abbott Laboratories Biomarkers and methods for detecting alzheimer's disease
ES2581178T3 (es) 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
US20110097747A1 (en) * 2009-10-26 2011-04-28 Kevin Jones Monoclonal antibody binds antigen associated with human tumors
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012037232A2 (en) * 2010-09-16 2012-03-22 University Of Miami Compositions, methods and kits for detecting and treating alzheimer's disease
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2012138284A1 (en) * 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
US9835621B2 (en) 2011-07-14 2017-12-05 University Of Kentucky Research Foundation Process for detection of alzheimer's disease from a serum sample
WO2013153461A2 (en) 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2014040042A2 (en) 2012-09-10 2014-03-13 The Johns Hopkins University Diagnostic assay for alzheimer's disease
US20140271463A1 (en) * 2013-03-12 2014-09-18 Stichting Vu-Vumc Bri2 as a novel biomarker for alzheimer's disease
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US20160186263A1 (en) 2013-05-09 2016-06-30 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
WO2015152724A2 (en) 2014-04-02 2015-10-08 Stichting Vu-Vumc Biomarkers for the detection of frontotemporal dementia
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
WO2017193115A1 (en) * 2016-05-06 2017-11-09 Nanosomix, Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
WO2017194995A1 (en) * 2016-05-11 2017-11-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for determining the temporal progression of a biological phenomenon and associated methods and devices
CN109791139A (zh) * 2016-08-09 2019-05-21 大塚制药株式会社 使用尿液生物标记的阿兹海默氏症的辅助诊断方法
JP6702836B2 (ja) * 2016-09-28 2020-06-03 ハルメク・ベンチャーズ株式会社 認知症判定得点算出装置及びそのプログラム
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
ES2600386B8 (es) * 2016-11-16 2017-08-04 Grifols Worldwide Operations Limited Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
JP6359159B2 (ja) * 2017-07-25 2018-07-18 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2019143562A1 (en) * 2018-01-18 2019-07-25 University Of North Texas Health Science Center At Fort Worth Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
EP3765065A2 (en) * 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019178562A1 (en) 2018-03-16 2019-09-19 Quest Diagnostics Investments Llc Methods for detecting chromogranin a by mass spectrometry
CN112703402A (zh) * 2018-07-19 2021-04-23 吉宁特有限公司 基于标志物分子将个体鉴定为具有淀粉样蛋白阳性痴呆症或处于发展淀粉样蛋白阳性痴呆症的风险中的方法和相关用途
CN113508300A (zh) * 2018-10-04 2021-10-15 曼尼托巴大学 用于人类阿尔茨海默病的新型生物标记物
US11621087B2 (en) 2019-09-24 2023-04-04 International Business Machines Corporation Machine learning for amyloid and tau pathology prediction
US11657189B2 (en) 2020-03-30 2023-05-23 Kyndryl, Inc. Object loss prevention using cognitive computing
JP7109499B2 (ja) * 2020-05-07 2022-07-29 一般社団法人脳と心の健康科学研究所 認知症判定得点算出装置及びそのプログラム
WO2022070798A1 (ja) * 2020-09-29 2022-04-07 康弘 橋本 アルツハイマー病病態鑑別用組み合わせマーカー及びそれを用いたアルツハイマー病病態鑑別方法
CN115066615A (zh) * 2020-12-28 2022-09-16 株式会社Mcbi 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
ES2235550T3 (es) * 1998-10-23 2005-07-01 Evotec Neurosciences Gmbh Metodos de diagnosticar o pronosticar la enfermedad de alzheimer.
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
WO2000066265A2 (en) 1999-04-27 2000-11-09 Ciphergen Biosystems, Inc. Probes for a gas phase ion spectrometer
EP1181705A2 (en) 1999-04-29 2002-02-27 Ciphergen Biosystems, Inc. Sample holder with hydrophobic coating for gas phase mass spectrometers
WO2001031580A2 (en) 1999-10-27 2001-05-03 Biowulf Technologies, Llc Methods and devices for identifying patterns in biological systems
US20020025527A1 (en) 2000-07-03 2002-02-28 Fiona Crawford Methods and assays for diagnosing alzheimer's disease
US6925389B2 (en) 2000-07-18 2005-08-02 Correlogic Systems, Inc., Process for discriminating between biological states based on hidden patterns from biological data
AU2002245043B2 (en) 2000-11-16 2006-10-26 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
CA2446666A1 (en) * 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7541003B2 (en) 2001-07-17 2009-06-02 Bio-Rad Laboratories, Inc. Latex based adsorbent chip
US7241873B2 (en) * 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US20030100016A1 (en) 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
US7276381B2 (en) 2002-01-25 2007-10-02 Bio-Rad Laboratories, Inc. Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
CA2745998C (en) * 2002-08-23 2013-11-26 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
US7632686B2 (en) * 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Similar Documents

Publication Publication Date Title
JP4796967B2 (ja) アルツハイマー病のためのバイオマーカー
JP2007524847A5 (https=)
Davidsson et al. The use of proteomics in biomarker discovery in neurodegenerative diseases
US20110313681A1 (en) Biomarkers for peripheral artery disease
KR20070043868A (ko) 암에 대한 혈소판 바이오마커
US20120172356A1 (en) Serum biomarkers for chagas disease
US7993868B2 (en) Saposin D and FAM3C are biomarkers for alzheimer's disease
US20130073308A1 (en) Methods of Detecting a Fragment of Neurosecretory Protein VGF for Diagnosing Alzheimer's Disease
WO2015152724A2 (en) Biomarkers for the detection of frontotemporal dementia
EP1907838B1 (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
Carrette et al. Proteomic Applications for Molecular Assessment of Alzheimer's Disease
HK1110388B (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease